Company
Innovative – Experienced – Growing.
SERDA is a clinical stage biopharmaceutical company. It is a joint venture between Smith & Nephew – one of the leading wound care companies – and NLC Health Ventures.
SERDA is developing a proprietary best-in-class fast and effective therapeutic product to treat major wounds, burn injuries and chronic ulcers.
SERDA has initiated its Phase I irritation study with data expected by end August 2024. This will be followed by a Phase Ib clinical study in Q4 2024 in patients with burn wounds, a major unmet clinical need in battlefield applications and natural disasters.
This clinical development program is also supported by the US Department of Defense with a grant of $2.5 million in collaboration with the Metis Foundation, under the United States Army Medical Research Acquisition Activity (USAMRAA) under Contract No. W81XWH22C0143.
